Myovant Sciences commences Phase III trial of relugolix to treat advanced prostate cancer

Clinical-stage biopharmaceutical company Myovant Sciences has commenced a Phase III clinical trial (HERO) of relugolix for the treatment of advanced prostate cancer.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news